文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.

作者信息

Schmidt Signe Tandrup, Khadke Swapnil, Korsholm Karen Smith, Perrie Yvonne, Rades Thomas, Andersen Peter, Foged Camilla, Christensen Dennis

机构信息

Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen Ø, Denmark; Statens Serum Institut, Department of Infectious Disease Immunology, Artillerivej 5, 2300 Copenhagen S, Denmark.

Aston Pharmacy School, Aston University, Birmingham B4 7ET, UK.

出版信息

J Control Release. 2016 Oct 10;239:107-17. doi: 10.1016/j.jconrel.2016.08.034. Epub 2016 Aug 26.


DOI:10.1016/j.jconrel.2016.08.034
PMID:27574990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5041310/
Abstract

A prerequisite for vaccine-mediated induction of CD8(+) T-cell responses is the targeting of dendritic cell (DC) subsets specifically capable of cross-presenting antigen epitopes to CD8(+) T cells. Administration of a number of cationic adjuvants via the intraperitoneal (i.p.) route has been shown to result in strong CD8(+) T-cell responses, whereas immunization via e.g. the intramuscular (i.m.) or subcutaneous (s.c.) routes often stimulate weak CD8(+) T-cell responses. The hypothesis for this is that self-drainage of the adjuvant/antigen to the lymphoid organs, which takes place upon i.p. immunization, is required for the subsequent activation of cross-presenting lymphoid organ-resident CD8α(+) DCs. In contrast, s.c. or i.m. immunization usually results in the formation of a depot at the site of injection (SOI), which hinders the self-drainage and targeting of the vaccine to cross-presenting CD8α(+) DCs. We investigated this hypothesis by correlating the biodistribution pattern and the adjuvanticity of the strong CD8(+) T-cell inducing liposomal cationic adjuvant formulation 09 (CAF09), which is composed of dimethyldioctadecylammonium bromide/monomycoloyl glycerol liposomes with polyinosinic:polycytidylic acid electrostatically adsorbed to the surface. Biodistribution studies with radiolabeled CAF09 and a surface-adsorbed model antigen [ovalbumin (OVA)] showed that a significantly larger fraction of the vaccine dose localized in the draining lymph nodes (dLNs) and the spleen 6h after i.p. immunization, as compared to after i.m. immunization. Studies with fluorescently labelled OVA+CAF09 demonstrated a preferential association of OVA+CAF09 to DCs/monocytes, as compared to macrophages and B cells, following i.p. immunization. Administration of OVA+CAF09 via the i.p. route did also result in DC activation, whereas no DC activation could be measured within the same period with unadjuvanted OVA and OVA+CAF09 administered via the s.c. or i.m. routes. In the dLNs, the highest level of activated, cross-presenting CD8α(+) DCs was detected at 24h post immunization, whereas an influx of activated, migrating and cross-presenting CD103(+) DCs to the dLNs could be measured after 48h. This suggests that the CD8α(+) DCs are activated by self-draining OVA+CAF09 in the lymphoid organs, whereas the CD103(+) DCs are stimulated by the OVA+CAF09 at the SOI. These results support the hypothesis that the self-drainage of OVA+CAF09 to the draining LNs is required for the activation of CD8α(+) DCs, while the migratory CD103(+) DCs may play a role in sustaining the subsequent induction of strong CD8(+) T-cell responses.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/722400aa967b/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/36ac45da3950/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/bfe1e58f197f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/0f7de6a1fca8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/c9713a2a393c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/4ff08758ee8d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/c2ad65f87921/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/702e2787b5f9/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/722400aa967b/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/36ac45da3950/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/bfe1e58f197f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/0f7de6a1fca8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/c9713a2a393c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/4ff08758ee8d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/c2ad65f87921/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/702e2787b5f9/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/5041310/722400aa967b/gr7.jpg

相似文献

[1]
The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.

J Control Release. 2016-10-10

[2]
Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.

Eur J Pharm Biopharm. 2019-5-2

[3]
Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).

Front Immunol. 2018-4-30

[4]
Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.

Vaccine. 2014-6-30

[5]
A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8 T Cells.

Front Immunol. 2018-11-27

[6]
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

J Immunol. 2011-5-25

[7]
Delivered antigen peptides to resident CD8α DCs in lymph node by micelle-based vaccine augment antigen-specific CD8 effector T cell response.

Eur J Pharm Biopharm. 2019-12-28

[8]
Transcutaneous immunization with a highly active form of XCL1 as a vaccine adjuvant using a hydrophilic gel patch elicits long-term CD8 T cell responses.

J Pharmacol Sci. 2020-4-10

[9]
Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node.

Proc Natl Acad Sci U S A. 2016-1-26

[10]
TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.

J Immunol. 2013-1-2

引用本文的文献

[1]
Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection.

EBioMedicine. 2025-3

[2]
Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants.

Vaccines (Basel). 2024-11-26

[3]
Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines.

Int J Mol Sci. 2024-10-25

[4]
Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID-19 vaccine.

Allergy. 2024-12

[5]
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.

J Immunother Cancer. 2024-5-23

[6]
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).

J Immunother Cancer. 2023-11-28

[7]
Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope.

Sci Rep. 2023-10-5

[8]
Vaccine adjuvants: mechanisms and platforms.

Signal Transduct Target Ther. 2023-7-19

[9]
Liposomal delivery system/adjuvant for tuberculosis vaccine.

Immun Inflamm Dis. 2023-6

[10]
First in man study: Bcl-Xl_42-CAF09b vaccines in patients with locally advanced prostate cancer.

Front Immunol. 2023

本文引用的文献

[1]
Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention.

J Immunol. 2015-3-1

[2]
Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.

Vaccine. 2014-6-30

[3]
Lymph-borne CD8α+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells.

Mucosal Immunol. 2015-1

[4]
Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses.

J Control Release. 2014-10-10

[5]
High-frequency vaccine-induced CD8⁺ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection.

Eur J Immunol. 2014-3-27

[6]
Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model.

J Virol. 2014-3-26

[7]
Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice.

Nanomedicine. 2014-4

[8]
Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy.

J Control Release. 2013-6-3

[9]
Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection.

J Immunol. 2013-5-10

[10]
Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles.

Biomaterials. 2013-3-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索